Methodological considerations for economic modelling of latent tuberculous infection screening in migrants

International Journal of Tuberculosis and Lung Disease

Volumn 21, Issue 9, 2017, Pages 977-989

  Shedrawy, J ^a   Siroka, A ^b   Oxlade, O ^c   Matteelli, A ^d   Lonnroth K ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Cost effectiveness; Economic modelling; Latent tuberculosis; Migrants; Screening

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; ECONOMIC MODEL; HUMAN; LATENT TUBERCULOSIS; MIGRANT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ECONOMICS; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; MASS SCREENING; META ANALYSIS (TOPIC); MIGRATION; TUBERCULIN TEST; TUBERCULOSIS;

COST-BENEFIT ANALYSIS; HUMANS; INCIDENCE; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MASS SCREENING; META-ANALYSIS AS TOPIC; MODELS, ECONOMIC; TRANSIENTS AND MIGRANTS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 85028046384     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.17.0134     Document Type: Article

References (61)

1. World Health Organization. Global tuberculosis report, 2016. WHO/HTM/TB/2016.13. Geneva, Switzerland: WHO, 2016.
2. Pareek M, Greenaway C, Noori T, Munoz J, Zenner D. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med 2016; 14: 48.
3. Langlois-Klassen D, Wooldrage KM, Manfreda J, et al. Piecing the puzzle together: foreign-born tuberculosis in an immigrantreceiving country. Eur Respir J 2011; 38: 895-902.
4. Lönnroth K, Mor Z, Erkens C, et al. TB in migrants in lowincidence countries: epidemiology and intervention entry points. Int J Tuberc Lung Dis 2017; 21: 624-636.
5. Zenner D, Hafezi H, Potter J, Capone S, Matteelli A. Effectiveness and cost-effectiveness of screening migrants for active tuberculosis and latent tuberculous infection. Int J Tuberc Lung Dis 2017; 21: 965-976.
6. Zammarchi L, Casadei G, Strohmeyer M, et al. A scoping review of cost-effectiveness of screening and treatment for latent tubercolosis infection in migrants from high-incidence countries. BMC Health Serv Res 2015; 15: 412.
7. Kunst H, Burman M, Arnesen T M, et al. Tuberculosis and latent tuberculosis infection screening of migrants in Europe: comparative analysis of policies, surveillance systems and results. Int J Tuberc Lung Dis 2017; 21: 840-851.
8. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46: 1563-1576.
9. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. Geneva, Switzerland: WHO, 2014.
10. Drummond M, Skulther M, Torrance G, O'Brien B, Stoddart G. Methods for economic evaluations of health care programmes. 3rd ed. New York, NY, USA: Oxford University Press, 2005.
11. Oxlade O, Pinto M, Trajman A, Menzies D. How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBI. PLoS ONE 2013; 8: e56044.
12. Koufopoulou M, Sutton A J, Breheny K, Diwakar L. Methods used in economic evaluations of tuberculin skin tests and interferon gamma release assays for the screening of latent tuberculosis infection: a systematic review. Value Health 2016; 19: 267-276.
13. Campbell J R, Sasitharan T, Marra F. A systematic review of studies evaluating the cost utility of screening high-risk populations for latent tuberculosis infection. Appl Health Econ Health Policy 2015; 13: 325-340.
14. Nienhaus A, Schablon A, Costa J T, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res 2011; 11: 247.
15. Auguste P, Tsertsvadze A, Court R, Pink J. A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups. Tuberculosis 2016; 99: 81-91.
16. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Cochrane Syst Rev 2015; 4(1): 1.
17. Wingate L T, Coleman M S, de la Motte Hurst C, et al. A costbenefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program. BMC Public Health 2015; 15: 1201.
18. Brassard P, Steensma C, Cadieux L, Lands L C. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a lowburden country. Pediatrics 2006; 117: e148-156.
19. Pareek M, Watson J P, Ormerod L P, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011; 11: 435-444.
20. Pareek M, Bond M, Shorey J, et al. Community-based evaluation of immigrant tuberculosis screening using interferon release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2012; 68: 230-239.
21. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26.
22. Haukaas F S, Arnesen T M, Winje B A, Aas E. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis. Eur J Health Econ 2017; 18: 405-415.
23. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries: a cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 161: 780-789.
24. Linas B P,Wong AY, Freedberg K A, Horsburgh C R J. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011; 184: 590-601.
25. Porco T C, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce S E. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health 2006; 6: 157.
26. Khan K, Muennig P, Behta M, Zivin J G. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002; 347: 1850-1859.
27. Socialstyrelsen. Rekommendationer för preventiva insatser mot tuberkulos - hälsokontroll, smittsp°arning och vaccination 2012. Stockholm, Sweden: Socialstyrelsen, 2012. https:// www. folkhal somyndighete n . se /page f i le s /20439/ rekommendationer-for-preventiva-insatser-mot-tuberkuloshalsokontroll- smittsparning-vaccination-2012-3-16.pdf. Accessed May 2017.
28. Kik S V, Olthof S P J, de Vries J T N, et al. Direct and indirect costs of tuberculosis among immigrant patients in the Netherlands. BMC Public Health 2009; 9: 283.
29. Foster N, Vassall A, Cleary S, Cunnama L, Churchyard G, Sinanovic E. The economic burden of TB diagnosis and treatment in South Africa. Soc Sci Med 2015; 130: 42-50.
30. de Cuevas RMA, Lawson L, Al-Sonboli N, et al. Patients direct costs to undergo TB diagnosis. Infect Dis Poverty 2016; 5: 24.
31. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients in low- and middleincome countries: a systematic review. Eur Respir J 2014; 43: 1763-1775.
32. Siegel J E, Weinstein M C, Russell L B, Gold M R. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276: 1339-1341.
33. World Health Organization. Guide to cost-effectiveness analysis. Geneva, Switzerland: WHO, 2003.
34. Trask L S. Chapter 1. Pharmacoeconomics: principles, methods, and applications. In: DiPiro J T, Talbert R L, Yee G C, Matzke G R,Wells B G, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 8th ed. New York, NY, USA: The McGraw-Hill Companies, 2011. http://mhmedical.com/ content.aspx?aid=7965001 Accessed May 2017.
35. Diel R, Lampenius N. Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs. Pharmacoeconomics 2014; 32: 617-626.
36. Brown J, Capocci S, Smith C, Morris S, Abubakar I, Lipman M. Health status and quality of life in tuberculosis. Int J Infect Dis 2015; 32: 68-75.
37. Guo N, Marra F, Marra C A. Measuring health-related quality of life in tuberculosis: a systematic review. Health Qual Life Outcomes 2009; 7: 14.
38. Abdulelah J, Sulaiman S A S, Hassali M A, Blebil A Q, Awaisu A, Bredle J M. Development and psychometric properties of a tuberculosis-specific multidimensional health-related qualityof- life measure for patients with pulmonary tuberculosis. Value Heal Reg Issues 2015; 6: 53-59.
39. Dujaili J A, Sulaiman S A S, HassaliMA, Awaisu A, Blebil A Q, Bredle J M. Health-related quality of life as a predictor of tuberculosis treatment outcomes in Iraq. Int J Infect Dis 2015; 31: 4-8.
40. Ozcaglar C, Shabbeer A, Vandenberg S L, Yener B, Bennett K P. Epidemiological models of Mycobacterium tuberculosis complex infections. Math Biosci 2012; 236: 77-96.
41. Barniol J, Niemann S, Louis V R, et al. Transmission dynamics of pulmonary tuberculosis between autochthonous and immigrant sub-populations. BMC Infect Dis 2009; 9: 197.
42. Kamper-Jorgensen Z, Andersen A B, Kok-Jensen A, et al. Migrant tuberculosis: the extent of transmission in a low burden country. BMC Infect Dis 2012; 12: 60.
43. Goldblatt D, Rorman E, Chemtob D, et al. Molecular epidemiology and mapping of tuberculosis in Israel: do migrants transmit the disease to locals? Int J Tuberc Lung Dis 2014; 18: 1085-1091.
44. Sandgren A, Schepisi M S, Sotgiu G, et al. Tuberculosis transmission between foreign- and native-born populations in the EU/EEA: a systematic review. Eur Respir J 2014; 43: 1159-1171.
45. World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva, Switzerland: WHO, 2015: 38.
46. Bibbins-Domingo K,GrossmanD C, Curry S J, et al. Screening for latent tuberculosis infection in adults. JAMA 2016; 316: 962.
47. Alsdurf H, Hill P C, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis 2016; 1269-1278.
48. Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf M J. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis 2016; 16: 204.
49. Stuurman A L, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets A M, Sandgren A, van der Werf M J. Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infect Dis 2016; 16: 257.
50. Hirsch-Moverman Y, Colson PW, Bethel J, Franks J, El-SadrW M. Can a peer-based intervention impact adherence to the treatment of latent tuberculous infection? Int J Tuberc Lung Dis 2013; 17: 1178-1185.
51. Tulsky J P, Hahn J A, Long H L, et al. Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Int J Tuberc Lung Dis 2004; 8: 83-91.
52. Nyamathi AM, Christiani A, Nahid P, Gregerson P, Leake B. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis 2006; 10: 775-782.
53. WhiteMC, Tulsky J P, Goldenson J, Portillo C J, Kawamura M, Menendez E. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med 2002; 162: 1044-1050.
54. Rocha C, Montoya R, Zevallos K, et al. The innovative socioeconomic Interventions Against Tuberculosis (ISIAT) project: an operational assessment. Int J Tuberc Lung Dis 2011; 15 (Suppl 2): S50-S57.
55. Hovell M F, Sipan C L, Blumberg E J, et al. Increasing Latino adolescents' adherence to treatment for latent tuberculosis infection: a controlled trial. Am J Public Health 2003; 93: 1871-1877.
56. Kominski G F, Varon S F, Morisky D E, et al. Costs and costeffectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial. J Adolesc Health 2007; 40: 61-68.
57. Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ 1997; 315: 1403-1406.
58. Goldberg S V, Wallace J, Jackson J C, Chaulk C P, Nolan C M. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis 2004; 8: 76-82.
59. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care 2005; 43 (Suppl): 5-14.
60. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8: iii-iv, ix-xi, 1-158.
61. Julian Higgins S G. Cochrane handbook for systematic reviews of interventions, version 5.1.0. London, UK: Cochrane, 2011.